DK1962889T3 - Immunogent polypeptid nestående af tumorantigenafledte optimerede kryptiske peptider samt anvendelser deraf - Google Patents

Immunogent polypeptid nestående af tumorantigenafledte optimerede kryptiske peptider samt anvendelser deraf

Info

Publication number
DK1962889T3
DK1962889T3 DK05850393T DK05850393T DK1962889T3 DK 1962889 T3 DK1962889 T3 DK 1962889T3 DK 05850393 T DK05850393 T DK 05850393T DK 05850393 T DK05850393 T DK 05850393T DK 1962889 T3 DK1962889 T3 DK 1962889T3
Authority
DK
Denmark
Prior art keywords
well
applications
tumor antigen
immunogenic polypeptide
polypeptide
Prior art date
Application number
DK05850393T
Other languages
English (en)
Inventor
Konstantinos Kosmatopoulos
Sebastien Cornet
Original Assignee
Vaxon Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vaxon Biotech filed Critical Vaxon Biotech
Application granted granted Critical
Publication of DK1962889T3 publication Critical patent/DK1962889T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
DK05850393T 2005-12-23 2005-12-23 Immunogent polypeptid nestående af tumorantigenafledte optimerede kryptiske peptider samt anvendelser deraf DK1962889T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2005/014212 WO2007073768A1 (en) 2005-12-23 2005-12-23 Immunogenic polypeptide composed of tumor antigen-derived optimized cryptic peptides, and uses thereof

Publications (1)

Publication Number Publication Date
DK1962889T3 true DK1962889T3 (da) 2009-11-02

Family

ID=36000393

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05850393T DK1962889T3 (da) 2005-12-23 2005-12-23 Immunogent polypeptid nestående af tumorantigenafledte optimerede kryptiske peptider samt anvendelser deraf

Country Status (12)

Country Link
US (1) US7973128B2 (da)
EP (1) EP1962889B1 (da)
JP (1) JP4929290B2 (da)
CN (1) CN101370513B (da)
AT (1) ATE435660T1 (da)
CA (1) CA2634480C (da)
DE (1) DE602005015368D1 (da)
DK (1) DK1962889T3 (da)
ES (1) ES2330658T3 (da)
PL (1) PL1962889T3 (da)
PT (1) PT1962889E (da)
WO (1) WO2007073768A1 (da)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010115229A1 (en) * 2009-04-09 2010-10-14 The University Of Melbourne Immunogenic composition and uses thereof
CN102153658A (zh) * 2011-01-19 2011-08-17 上海科医联创生物科技有限公司 肿瘤抗原、dc肿瘤疫苗及其制备方法
EP2886127A1 (en) 2013-12-18 2015-06-24 Vaxon Biotech Method for emulsifying a triepitope peptide with montanide and kits for performing the same
EP2977059A1 (en) 2014-07-22 2016-01-27 Vaxon Biotech Immunogenic polypeptide composed of HLA-B7 restricted tumor antigen-derived optimized cryptic peptides, and uses thereof
CN104926944B (zh) * 2015-05-22 2018-04-13 北京康爱瑞浩生物科技股份有限公司空港分公司 多靶点复合抗原负载cd8+细胞毒性t淋巴细胞的制备方法及其用途
CN116710115A (zh) 2020-11-20 2023-09-05 思维疗法股份有限公司 用于优化的肽疫苗的组合物和方法
US11421015B2 (en) 2020-12-07 2022-08-23 Think Therapeutics, Inc. Method of compact peptide vaccines using residue optimization
US11058751B1 (en) 2020-11-20 2021-07-13 Think Therapeutics, Inc. Compositions for optimized RAS peptide vaccines
US11464842B1 (en) 2021-04-28 2022-10-11 Think Therapeutics, Inc. Compositions and method for optimized peptide vaccines using residue optimization

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2087401A (en) 1999-12-10 2001-06-18 Epimmune, Inc. Inducing cellular immune responses to her2/neu using peptide and nucleic acid compositions
DK1282702T3 (da) * 2000-05-10 2007-04-02 Sanofi Pasteur Ltd Immunogene polypeptider, som er kodet af KAGE-minigener, og anvendelser deraf
FR2812087B1 (fr) * 2000-07-21 2007-05-11 Inst Nat Sante Rech Med Procede de criblage de peptides utilisables en immunotherapie

Also Published As

Publication number Publication date
ATE435660T1 (de) 2009-07-15
CA2634480C (en) 2013-10-15
JP4929290B2 (ja) 2012-05-09
DE602005015368D1 (de) 2009-08-20
ES2330658T3 (es) 2009-12-14
CA2634480A1 (en) 2007-07-05
PT1962889E (pt) 2009-10-14
JP2009520472A (ja) 2009-05-28
US20090130133A1 (en) 2009-05-21
EP1962889A1 (en) 2008-09-03
PL1962889T3 (pl) 2010-03-31
CN101370513B (zh) 2013-04-03
WO2007073768A1 (en) 2007-07-05
CN101370513A (zh) 2009-02-18
US7973128B2 (en) 2011-07-05
EP1962889B1 (en) 2009-07-08

Similar Documents

Publication Publication Date Title
PT2121731E (pt) Vacinas peptídicas para cancros que expressam antigénios associados a tumores
NZ593598A (en) Optimized antiviral vaccines with improved cellular immunogenicity
EP1548032A4 (en) KDR-PEPTIDES AND VACCINES CONTAINING THEM
CA2817709C (en) Consensus prostate antigens, nucleic acid molecule encoding the same and vaccine and uses comprising the same
UA110599C2 (uk) Пептид для імунотерапії пухлин, включаючи нейрональні пухлини та пухлини мозку
IL214460A0 (en) Malaria prime/boost vaccines
NZ702145A (en) Bluetongue virus recombinant vaccines and uses thereof
MXPA02006888A (es) Flavivirus recombinantes y metodos para utilizar los mismos.
ATE473238T1 (de) Tuberkulose vaccine mit verbesserter effizienz
AR049177A1 (es) Polipeptidos y conjugados de interferon-alfa
MX2009007261A (es) Vacuna de peptido foxp3.
NZ598605A (en) Vaccine against african horse sickness virus
CY1112867T1 (el) Πεπτιδια επιτοπων που προερχονται απο τον υποδοχεα 1 του αγγειακου ενδοθηλιακου αυξητικου παραγοντα και εμβολια περιεχοντας αυτα τα πεπτιδια
DK1962889T3 (da) Immunogent polypeptid nestående af tumorantigenafledte optimerede kryptiske peptider samt anvendelser deraf
MX2010005816A (es) Epítopos de péptido de stat3.
MX2010010025A (es) Proteina de fusion con direccionamiento de antigenos vacunales a celulas presentadoras de antigeno y sus aplicaciones.
WO2009083968A8 (en) Novel protein
EP4047009A3 (en) Wdrpuh epitope peptides and vaccines containing the same
WO2009149094A3 (en) Cytotoxic t cell defined egfr peptide and an optimized derivative peptide
AR041243A1 (es) Vacuna para ostertagia
PE20001367A1 (es) Sintesis recombinante de beta-lipotropina y otros peptidos
TH88495B (th) วัคซีนชนิดใหม่สำหรับปรสิตทางทะเล
WO2006134280A3 (fr) Sequences nucleotidiques mutees du virus de l'hepatite c
CY1114720T1 (el) Πεπτιδια επιτοπων που προερχονται απο τον υποδοχεα 1 του αγγειακου ενδοθηλιακου αυξητικου παραγοντα και εμβολια περιεχοντας αυτα τα πεπτιδια
MX339085B (es) Inmunogeno recombinante para la produccion de antivenenos contra el veneno de alacranes del genero parabuthus.